Ramirez Juan C, Lacey Mitchel E, Gowda Maya S, Wang Grace, Chamorro Yolcar, Sandoval-Leon Ana C
Department of Medical Education, Florida International University Herbert Wertheim College of Medicine, Miami, FL.
College of Agriculture and Life Sciences, Cornell University, Ithaca, NY.
Medicine (Baltimore). 2025 Mar 28;104(13):e41906. doi: 10.1097/MD.0000000000041906.
Hemorrhagic cystitis can be a serious side effect of some chemotherapy drugs like cyclophosphamide and ifosfamide. Docetaxel is a taxane that is used to treat several malignancies including breast and prostate cancer. Hemorrhagic cystitis has not been described as a complication of combination chemotherapy with docetaxel, particularly docetaxel with carboplatin, trastuzumab and pertuzumab (TCHP) in breast cancer patients.
Both patients had a history of locally advanced human epidermal growth factor receptor 2 positive breast cancer and complaint of hematuria after their first treatment with TCHP.
They were diagnosed with hemorrhagic cystitis.
Docetaxel was discontinued and changed to paclitaxel.
Both patients completed neoadjuvant chemotherapy and did not have further episodes of hemorrhagic cystitis.
Hemorrhagic cystitis is a rare complication of combination chemotherapy with docetaxel (TCHP). Clinicians should be vigilant for signs and symptoms of hemorrhagic cystitis in patients receiving docetaxel and alternative treatment option should be considered.
出血性膀胱炎可能是某些化疗药物（如环磷酰胺和异环磷酰胺）的严重副作用。多西他赛是一种紫杉烷类药物，用于治疗多种恶性肿瘤，包括乳腺癌和前列腺癌。出血性膀胱炎尚未被描述为多西他赛联合化疗的并发症，尤其是在乳腺癌患者中多西他赛与卡铂、曲妥珠单抗和帕妥珠单抗（TCHP）联合使用时。
两名患者均有局部晚期人表皮生长因子受体2阳性乳腺癌病史，且在首次接受TCHP治疗后出现血尿症状。
他们被诊断为出血性膀胱炎。
停用多西他赛，改为使用紫杉醇。
两名患者均完成了新辅助化疗，且未再出现出血性膀胱炎发作。
出血性膀胱炎是多西他赛联合化疗（TCHP）的罕见并发症。临床医生应对接受多西他赛治疗的患者的出血性膀胱炎症状和体征保持警惕，并应考虑替代治疗方案。
